New insider activity at Serina Therapeutics ( (SER) ) has taken place on August 27, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSO Moreadith Randall recently made headlines by selling 47,674 shares of Serina Therapeutics stock, amounting to a significant transaction worth $331,417.
Recent Updates on SER stock
In the past 24 hours, Serina Therapeutics experienced significant stock movement, with trading temporarily halted due to volatility. The stock soared by 20% following the FDA’s support for advancing their SER-252 clinical study program for Parkinson’s disease. This support came after a Type B meeting where the FDA provided positive feedback on Serina’s proposed clinical study design. Additionally, Serina announced amendments to its bylaws to enhance governance transparency, which may impact legal dispute management. Despite these positive developments, the company faces financial challenges, with negative profitability and mixed technical signals affecting its stock score. However, advancements in their drug candidate SER-270 for tardive dyskinesia and the FDA’s backing contribute to a more optimistic outlook for future growth.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
Serina Therapeutics faces significant financial challenges, which heavily impact its overall stock score. The technical analysis provides mixed signals, and the valuation is unattractive due to negative profitability. However, the recent corporate event regarding SER-270 offers a positive outlook for future growth potential. The overall score reflects these mixed factors, with financial performance being the most significant detractor.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
YTD Price Performance: 7.65%
Average Trading Volume: 111,002
Technical Sentiment Signal: Sell
Current Market Cap: $56.28M